.

• A 60-page Executive InformationalOverview® (EIO) written by Crystal Research Associates on CardioComm Solutions, Inc. is available at www.crystalra.com.

• Covers a range of topics:

o CardioComm’s cardiac monitoring products

o Market opportunities

o Software platforms

o Additional products and technologies

o Competition

o …and other key fundamentals.

New Independent Equity Research

.

• Our Executive Informational Overview® (EIO) presents a crystal clear, detailed report on a company in a manner that is easily understood by the Wall Street financial community.

• It details a company’s product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other fundamental information.

• It is free of investment ratings, target prices, and forward-looking financial models.

• Complete risks and disclosures are included within each EIO.

• Our trademarked EIOs are exclusively written by experienced, award-winning analysts at Crystal Research Associates, LLC.

What is an EIO?

.

Excerpts from our EIO on

CardioComm Solutions, Inc. (EKG-TSX.V)

THE FIRST FDA-CLEARED, HANDHELD, OVER-THE-COUNTER ECG MONITOR FOR PATIENT DIAGNOSIS AND MANAGEMENT

.

Overview of CardioComm Solutions

• Information management systems and bio-monitoring devices for the cardiac and telemedicine markets

• Electrocardiogram (ECG) and arrhythmia monitoring products and services enable quick and easy management of patient information

o ECG recordings from anywhere in the world

o Record, view, analyze, and store patients’ ECGs for diagnosis and treatment of cardiac disorders

.

• Recently introduced a handheld ECG recording device called the HeartCheck™ PEN ECG

o the first in-home, consumer-targeted health monitoring technology for OTC markets in the past 30 years.

• HeartCheck™ is supported by software programs and patent-pending “SMART Monitoring services”

o Enables 24/7 patient monitoring and objective medical interpretation

o Capacity for integrating ECG reporting into existing electronic medical records (EMRs)

Products and Services

.

• Heart disease affects people of every race and is the leading cause of death worldwide.

• In the U.S., the CDC estimates that approximately 715,000 heart attacks and 795,000 strokes occur each year.

o Strokes kill someone in the U.S. every four minutes, on average.

• Roughly 50% of deaths from heart attacks happen before the patient has a chance to seek help.

By providing accurate and immediate cardiac data, patient monitoring technologies such as CardioComm’s

could increase the likelihood of surviving a severe cardiac event.

Market Opportunities

.

• The remote and wireless patient monitoring market has significant growth potential.

• The U.S. leads the world in spending for remote cardiac monitoring.

• According to research from iSuppli Corp., part of global information provider IHS Inc. (IHS-NYSE), this market had a value in the U.S. of $686 million as of 2011, which is forecast to expand by 27% to reach $867 million in 2016.Data Source: IHS iSuppli’s March 4, 2013, press release

Market Opportunities

Source: IHS InMedica Research, February 2012.

Millio

ns of

U.S.

Dollar

s

FORECAST OF U.S. MARKET FOR REMOTE CARDIAC MONITORING SERVICES ($MM)

.

• Technology was rated as “the best enabling technology for cardiac rhythm monitoring” in 2012 by Frost & Sullivan

Awards and Recognition

.

To read the entire 60-page EIO on CardioComm Solutions Inc. (EKG-TSX.V) or find information on other companies

under our coverage, please visit www.crystalra.com.

.

Crystal Research Associates, LLC (www.crystalra.com) is an independent research firm that has provided institutional-quality research on small- and mid-cap companies for the past decade. We are led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the international financial media for his years of work on Wall Street and for providing consistent award-winning analyses and developing long-term relationships on both the buy-side and sell-side. He has been consistently ranked among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally, Mr. Kraws has been 5-Star ranked for top biotechnology stock performance by Starmine.

About Us

Corporate Headquarters:880 Third Avenue, 6th FloorNew York, NY 10022Office: (212) 851-6685Fax: (609) 395-9339

Satellite Office Location:2500 Quantum Lakes Drive, Suite 203Boynton Beach, FL 33426Office: (561) 853-2234Fax: (561) 853-2246

Jeffrey J. KrawsCEO, Crystal Research Associates